GILD Stock Analysis: Gilead Sciences | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 195.132m USD | 12M Return: 27.4% | US3755581036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 818M
Qual. Beats: 1
Rev. Trend: 97.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Gilead Sciences is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs across the United States, Europe, and international markets. Its portfolio spans several therapeutic areas, including HIV (Biktarvy, Descovy, Sunlenca), viral hepatitis (Epclusa, Vemlidy), oncology cell therapies (Yescarta, Tecartus, Trodelvy), serious fungal infections (AmBisome), and COVID-19 (Veklury). The company also pursues immunotherapies for cancer and other intractable diseases.
Gilead operates a diversified pipeline supported by numerous external partnerships and licensing agreements with entities such as Arcus Biosciences, Merck, Janssen, Everest Medicines, and LEO Pharma, among others. The company was incorporated in 1987 and is headquartered in Foster City, California.
As a large-cap biotechnology firm, Gileads business model centers on high-risk, high-reward drug development, where revenue is generated primarily through the commercialization of patented therapeutics and supplemented by milestone payments and royalties from collaboration partners. The companys heavy reliance on a few blockbuster franchises, particularly in HIV, makes its financial performance sensitive to patent expirations, pipeline success, and regulatory approvals in its key markets.
- Lenacapavir PrEP approval drives HIV prevention revenue
- Trodelvy and Yescarta CAR-T sales growth offsets declines
- Hepatitis C franchise continues eroding as patient pool shrinks
| Net Income: -3.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 9.93 > 1.0 |
| NWC/Revenue: 9.60% < 20% (prev 12.23%; Δ -2.62% < -1%) |
| CFO/TA 0.27 > 3% & CFO 13.6b > Net Income -3.24b |
| Net Debt (23.1b) to EBITDA (1.80b): 12.79 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.24b) vs 12m ago -0.96% < -2% |
| Gross Margin: 79.59% > 18% (prev 78.53%; Δ 1.05% > 0.5%) |
| Asset Turnover: 57.97% > 50% (prev 51.80%; Δ 6.17% > 0%) |
| Interest Coverage Ratio: -0.96 > 6 (EBIT TTM -957.0m / Interest Expense TTM 998.0m) |
| A: 0.06 (Total Current Assets 13.9b - Total Current Liabilities 11.0b) / Total Assets 49.4b |
| B: 0.04 (Retained Earnings 2.20b / Total Assets 49.4b) |
| C: -0.02 (EBIT TTM -957.0m / Avg Total Assets 52.5b) |
| D: 0.31 (Book Value of Equity 11.8b / Total Liabilities 37.6b) |
| Altman-Z'' = 0.74 = B |
| DSRI: 1.00 (Receivables 5.05b/4.78b, Revenue 30.5b/28.9b) |
| GMI: 0.99 (GM 78.53% / 79.59%) |
| AQI: 0.94 (AQ_t 0.60 / AQ_t-1 0.64) |
| SGI: 1.06 (Revenue 30.5b / 28.9b) |
| TATA: -0.34 (NI -3.24b - CFO 13.6b) / TA 49.4b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 20, 2026, the stock is trading at USD 153.07 with a total of 5,603,491 shares traded. Over the past week, the price has changed by +1.75%, over one month by +1.67%, over three months by +15.56% and over the past year by +27.41%.
Current recommended Stop Loss: 146.70 (which is 4.2% or 1.7 ATR below the current price).
Gilead Sciences has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy GILD.
- StrongBuy: 16
- Buy: 6
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 159.9 | 4.4% |
P/E Forward = 15.5521
P/S = 6.4068
P/B = 16.0047
P/EG = 2.2696
Revenue TTM = 30.5b USD
EBIT TTM = -957.0m USD
EBITDA TTM = 1.80b USD
Long Term Debt = 23.8b USD (from longTermDebt, last quarter)
Short Term Debt = 2.41b USD (from shortTermDebt, last quarter)
Debt = 26.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.1b USD (calculated: Debt 26.2b - CCE 3.18b)
Enterprise Value = 218b USD (195b + Debt 26.2b - CCE 3.18b)
Interest Coverage Ratio = -0.96 (Ebit TTM -957.0m / Interest Expense TTM 998.0m)
EV/FCF = 16.53x (Enterprise Value 218b / FCF TTM 13.2b)
FCF Yield = 6.05% (FCF TTM 13.2b / Enterprise Value 218b)
FCF Margin = 43.34% (FCF TTM 13.2b / Revenue TTM 30.5b)
Net Margin = -10.64% (Net Income TTM -3.24b / Revenue TTM 30.5b)
Gross Margin = 79.59% ((Revenue TTM 30.5b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 79.76% (prev 79.24%)
Tobins Q-Ratio = 4.42 (Enterprise Value 218b / Total Assets 49.4b)
Interest Expense / Debt = 3.80% (Interest Expense 998.0m / Debt 26.2b)
Taxrate = 13.13% (1.29b / 9.80b)
NOPAT = -831.4m (EBIT -957.0m * (1 - 13.13%)) [loss with tax shield]
Current Ratio = 1.27 (Total Current Assets 13.9b / Total Current Liabilities 11.0b)
Debt / Equity = 2.22 (Debt 26.2b / totalStockholderEquity, last quarter 11.8b)
Debt / EBITDA = 12.79 (Net Debt 23.1b / EBITDA 1.80b)
Debt / FCF = 1.75 (Net Debt 23.1b / FCF TTM 13.2b)
Total Stockholder Equity = 19.9b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.17% (Net Income -3.24b / Total Assets 49.4b)
RoE = -16.28% (Net Income TTM -3.24b / Total Stockholder Equity 19.9b)
RoCE = -2.19% (EBIT -957.0m / Capital Employed (Equity 19.9b + L.T.Debt 23.8b))
RoIC = -2.12% (negative operating profit) (NOPAT -831.4m / Invested Capital 39.2b)
WACC = 5.94% (E(195b)/V(221b) * Re(6.29%) + D(26.2b)/V(221b) * Rd(3.80%) * (1-Tc(0.13)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -14.51 | Cagr: -0.14%
[DCF] Terminal Value 77.97% ; FCFF base≈11.7b ; Y1≈13.4b ; Y5≈19.7b
[DCF] Fair Price = 220.3 (EV 296b - Net Debt 23.1b = Equity 273b / Shares 1.24b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.84 | # QB: 1
Revenue Correlation: 97.85 | Revenue CAGR: 3.95% | SUE: 1.82 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.20 | Chg30d=+2.42% | Revisions=+22% | Analysts=22
EPS current Year (2026-12-31): EPS=-0.40 | Chg30d=+6.19% | Revisions=+50% | GrowthEPS=-104.9% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=9.95 | Chg30d=+0.58% | Revisions=+30% | GrowthEPS=+2587.5% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: +43% (up=15, down=5)